Why Was My GLP-1 Prior Authorization Denied?
Your GLP-1 prior authorization was denied for a specific reason, and the letter has to say what it is. The U.S. Department of Labor's claims guide says a denial based on an internal rule, guideline or protocol must describe it or offer you a free copy. Ask for that copy. It is the answer key to your appeal.
The usual reasons: weight-loss drugs are excluded, the request lacked a BMI or weight-related condition, the indication does not match (Ozempic for weight loss is the classic), the plan wants another treatment first, or the drug is off the formulary. Exclusions are common. KFF's 2025 Employer Health Benefits Survey found that 43% of firms with 5,000 or more workers cover GLP-1s for weight loss, against 16% of firms with 200 to 999 workers, and 34% of covering firms require a dietitian, case manager, therapist or lifestyle program.
Our rule of thumb: a paperwork denial is very fixable, a medical necessity denial is winnable, and a contract exclusion is the hardest fight, because you are arguing with the plan document itself. Our GLP-1 insurance coverage guide explains how formularies and weight-management benefits work.
How Long Do You Have to Appeal a GLP-1 Denial?
Under the Affordable Care Act rules summarized on HealthCare.gov, you have 180 days from the denial notice to file an internal appeal, and the Department of Labor calls that a minimum. Medicare Part D gives you only 65 days, according to Medicare.gov. Put the date in your calendar today.
The plan has deadlines too. HealthCare.gov says an appeal for a service you have not received yet must be decided within 30 days, or within 4 business days if urgent. After a final denial you have 4 months to request an external review, decided within 45 days or 72 hours if expedited, and your insurer is required by law to accept the result. The federal HHS process is free; other processes cannot charge more than $25.
How to Appeal a GLP-1 Denial, Step by Step
A strong GLP-1 appeal answers the plan's written criteria line by line with dated evidence. The reviewer is checking your file against a list, so hand the list back, filled in.
- Get the denial letter and the plan's clinical criteria for the drug, in writing.
- Match each criterion to a dated document: BMI, weight-related condition, required programs or earlier drugs.
- Ask your prescriber for a letter of medical necessity that names the FDA-approved indication.
- If the drug is off the formulary, file an exception request as well.
- Send it before the deadline with your name, claim number and member ID, as HealthCare.gov advises, and keep copies.
- If the internal appeal fails, request external review within 4 months.
The indication matters more than people expect. The Zepbound prescribing information covers weight reduction in adults with obesity, or with overweight plus a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity. The Wegovy prescribing information adds cardiovascular risk reduction and MASH. Our GLP-1 eligibility guide covers the clinical criteria.
Off-formulary requests move fast. Under 45 CFR 156.122, a plan covering essential health benefits must decide a standard exception within 72 hours, or 24 hours in exigent cases, which include being mid-treatment on the drug.
Your prescriber signs the letter, so talk to your prescriber's office before you draft anything. And never round a BMI up or backdate a diagnosis to clear a cutoff. That is insurance fraud.
Which Fix Matches Your Denial Reason?
The right next move for a GLP-1 denial depends on the reason printed on the letter, so start there, not with a template.
| Reason on the letter | What it means | Next move |
|---|---|---|
| Criteria not met | Missing BMI, condition or required program | Resubmit or appeal with matching chart notes |
| Not medically necessary | A reviewer judged the drug unnecessary | Letter of medical necessity, then external review |
| Non-formulary | The drug is not on the plan's list | Exception request: 72 hours standard, 24 hours exigent |
| Try another treatment first | Another drug or a lifestyle program comes first | Document what you tried, or complete the step |
| Benefit excluded | The contract leaves out weight-loss drugs | Check other FDA indications; ask HR about next year |
| Medicare GLP-1 Bridge | The central processor rejected the request | No appeal; prescriber resubmits a corrected form |
Summarized from HealthCare.gov, the Department of Labor, 45 CFR 156.122, Medicare.gov, CMS and the FDA prescribing information listed under Sources. Your plan's own documents govern your case.
What If You Are on Medicare?
On Medicare, the first question is which door your GLP-1 went through, because only one has appeal rights. CMS routes type 2 diabetes, moderate to severe sleep apnea and MASH through your regular Part D plan, where Medicare.gov sets the usual steps: a redetermination decided within 7 days, or 72 hours if expedited, then an Independent Review Entity.
Weight management alone runs through the Medicare GLP-1 Bridge, a CMS demonstration from July 1, 2026 to December 31, 2027 with a $50 copay for Foundayo, Wegovy and the Zepbound KwikPen. Eligibility is judged when you start therapy: a BMI of at least 35, or 30 with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a or higher kidney disease, or 27 with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
The catch: CMS states there is no appeals process under the Bridge, and your prescriber can only resubmit the form with corrected information. So get it right the first time. CMS asks prescribers to add an obesity diagnosis code and the note SEND TO BRIDGE FOR WEIGHT MANAGEMENT; without them, the pharmacy may bill your Part D plan, which may reject the claim.
What If the Appeal Still Fails?
If your final internal GLP-1 appeal fails, request an external review, because the reviewer's decision binds the insurer and almost nobody asks for one. KFF counted at least 5,881 external appeals in HealthCare.gov plans in 2024, just 4% of the denials upheld internally, and insurers upheld 66% of internal appeals that year. Those figures cover all claims, not GLP-1s. We found no verified GLP-1 appeal success rate, so be skeptical of anyone quoting one.
If your plan excludes weight-loss drugs outright, ask HR about next year's plan, compare self-pay prices in our GLP-1 cost guide, and read our compounded GLP-1 guide before a cheap offer tempts you. Talk to your prescriber before switching drugs or pausing treatment while you wait. More plain-language answers sit in our GLP-1 guides.
Frequently Asked Questions
A GLP-1 prior authorization appeal for a medication you have not received yet must be decided within 30 days, or within 4 business days if urgent, according to HealthCare.gov. External review takes up to 45 days, or 72 hours if expedited. Medicare Part D redeterminations take up to 7 days, or 72 hours if expedited.
You can appeal a weight-loss drug exclusion, but it is a contract term rather than a clinical judgment, so it is the hardest denial to overturn. Ask your prescriber whether another FDA-approved indication fits, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea. Never overstate a diagnosis to fit a coverage rule.
A letter of medical necessity for Wegovy or Zepbound should answer the plan's written criteria point by point: the diagnosis and FDA-approved indication, a dated BMI, weight-related conditions, anything the plan required you to try first, and why this drug fits you. The Department of Labor says the plan must give you its denial guidelines free on request.
Want a Clinician in Your Corner?
Licensed online GLP-1 programs vary on insurance. Some help with prior authorization documentation, others are cash-pay only, and none can guarantee your plan will approve coverage. Ask before you enroll.
Prescription required. Medical screening and clinician review required. Not all patients will qualify. Affiliate disclosure: this site may earn a referral fee from programs listed.
Compare Online GLP-1 ProgramsSources
The following sources were used for the appeal rules, program criteria, prescribing information and survey data referenced on this page. Always verify against the most current version of each document.
- HealthCare.gov: Internal appeals: 180 days to file, 30-day decisions for services not yet received, urgent appeals within 4 business days, and what to include.
- HealthCare.gov: External review: 4 months to request, 45-day standard and 72-hour expedited decisions, insurer required by law to accept the decision, cost limits.
- U.S. Department of Labor, EBSA: Filing a Claim for Your Health Benefits: at least 180 days to appeal, denial notice contents, and free copies of the rules, guidelines and documents used to deny a claim.
- 45 CFR 156.122, Prescription drug benefits (Electronic Code of Federal Regulations): standard exception decisions within 72 hours, expedited decisions within 24 hours, and the definition of exigent circumstances.
- Medicare.gov: Appeals in a Medicare drug plan: 65 days to request a redetermination, 7-day and 72-hour decisions, prescriber statements for exceptions, and the Independent Review Entity step.
- CMS: Medicare GLP-1 Bridge, Information for Providers: program dates, $50 copay, central processor, and the statement that there is no appeals process.
- CMS: Medicare GLP-1 Bridge, Information for Prescribers (June 2026): eligibility criteria at therapy start, covered formulations, and the prescription note for weight management.
- Wegovy (semaglutide) US Prescribing Information, Novo Nordisk: indications for weight reduction, cardiovascular risk reduction and MASH.
- Zepbound (tirzepatide) US Prescribing Information, Eli Lilly: indications for weight reduction and obstructive sleep apnea in adults with obesity.
- KFF: Claims Denials and Appeals in ACA Marketplace Plans in 2024 (March 2026): appeal rate under 1%, 66% of appeals upheld, and at least 5,881 external appeals.
- KFF: 2025 Employer Health Benefits Survey (October 2025): GLP-1 coverage for weight loss by firm size and lifestyle program requirements.